As the coronavirus vaccines become more accessible in the United States, two infectious disease experts from Georgetown University Medical Center assert that protecting oneself against the presymptomatic and asymptomatic spread of the SARS-CoV-2 virus, which causes the coronavirus, is the key to ending the pandemic.
Both from the Georgetown University Center for Global Health Science and Security, Saskia V. Popescu and Angela L. Rasmussen published their research on the transmission of SARS-CoV-2 without symptoms in the “Science” journal on March 19. The researchers both claim that the symptomless transmission of the virus silently increases the spread of the virus and is crucial to putting an end to the pandemic.
In their research, the authors stated that determining the transmission capability of presymptomatic and asymptomatic cases was complicated, adding that despite this, knowledge gaps shouldn’t keep researchers from recognizing the role they play in the spread of SARS-CoV-2.
The coronavirus is a serious acute respiratory syndrome that has a long incubation period and spreads even among individuals who don’t know that they are infected. Rasmussen stated that while vaccines were great at protecting individuals against various ailments, people shouldn’t rely on vaccination alone to control the coronavirus pandemic, noting that no one knows how well the vaccines will work to protect people against transmission.
She added that from a biological perspective, it is highly unlikely that a vaccine that protected well against ailments would not protect against infections. However, while the vaccines do offer protection, they don’t provide 100% protection against getting sick, which means that they also aren’t 100% likely to offer protection against viral transmission.
In addition, while vaccines will become widely accessible in the United States by the time summer comes around, this will not be the case for the rest of the world, where the pandemic rages on unrelentingly.
Popescu noted that presymptomatic and asymptomatic transmission of the virus posed a challenge to efforts to prevent the number of infections from growing. In the long run, Popescu stated, the virus is something that would need to continuously be observed as the world sees a decrease in the rate of infection because of vaccinations and goes into the next phase of the coronavirus pandemic.
Popescu and Rasmussen came to the conclusion that until there was extensive implementation of strong epidemiological and surveillance measures that would allow officials to put an end to transmission once and for all, the coronavirus pandemic could not be fully stamped out.
The research community isn’t only engaged in finding solutions to the coronavirus scourge. Plenty of research effort is also being directed at different forms of cancer, and CNS Pharmaceuticals Inc. (NASDAQ: CNSP) has made it its mission to seek for remedies to cancers that afflict the brain as well as the central nervous system.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Roughly two-thirds of the world’s population lacks access to basic imaging technology, and the radiologist…
The FDA IND approval marks a pivotal step for the company's lead compound, known as…
Cancer care has evolved over the past decades and one would expect that the more…
In the United States alone, close to one million people are living with MS, with…
A nationwide survey conducted by the Commonwealth Fund has found that contrary to a common…
Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that…